ARS Pharmaceuticals, Inc. Diluted Shares Outstanding (Weighted Average)
ARS Pharmaceuticals, Inc. (SPRY) reported Diluted Shares Outstanding (Weighted Average) of 99.31 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 99.31M shares, a 0.97% increase year-over-year.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 99.30M shares, a 1.26% increase year-over-year.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 99.03M shares, a 16.93% decline year-over-year.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 98.81M shares, a 1.83% increase year-over-year.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 98.57M shares, a 3.74% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 102.39M shares, a 7.54% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 95.22M shares, a 138.30% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 39.96M shares, a 38.39% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 99.31M shares 10-Q · filed 2026-08-13 | 99.30M shares 10-Q · filed 2026-08-13 | 99.21M shares derived: average of 3 quarters · filed 2026-08-13 | 99.11M shares derived: average of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | 99.30M shares 10-Q · filed 2026-05-15 | 99.16M shares derived: average of 2 quarters · filed 2026-05-15 | 99.04M shares derived: average of 3 quarters · filed 2026-05-15 | 98.87M shares derived: average of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | 99.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 98.92M shares derived: average of 2 quarters · filed 2026-03-09 | 98.73M shares derived: average of 3 quarters · filed 2026-08-13 | 98.57M shares 10-K · filed 2026-03-09 | ||
| 2025-09-30 | 98.81M shares 10-Q · filed 2025-11-10 | 98.58M shares derived: average of 2 quarters · filed 2026-08-13 | 98.41M shares 10-Q · filed 2025-11-10 | 103.61M shares derived: average of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | 98.36M shares 10-Q · filed 2026-08-13 | 98.21M shares 10-Q · filed 2026-08-13 | 105.21M shares derived: average of 3 quarters · filed 2026-08-13 | 103.17M shares derived: average of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | 98.06M shares 10-Q · filed 2026-05-15 | 108.64M shares derived: average of 2 quarters · filed 2026-05-15 | 104.77M shares derived: average of 3 quarters · filed 2026-05-15 | 102.78M shares derived: average of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | 119.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 108.12M shares derived: average of 2 quarters · filed 2026-03-09 | 104.36M shares derived: average of 3 quarters · filed 2026-03-09 | 102.39M shares 10-K · filed 2026-03-09 | ||
| 2024-09-30 | 97.03M shares 10-Q · filed 2025-11-10 | 96.93M shares derived: average of 2 quarters · filed 2025-11-10 | 96.78M shares 10-Q · filed 2025-11-10 | 96.62M shares derived: average of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | 96.83M shares 10-Q · filed 2025-08-13 | 96.66M shares 10-Q · filed 2025-08-13 | 96.48M shares derived: average of 3 quarters · filed 2025-08-13 | 96.26M shares derived: average of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | 96.49M shares 10-Q · filed 2025-05-14 | 96.31M shares derived: average of 2 quarters · filed 2025-05-14 | 96.06M shares derived: average of 3 quarters · filed 2025-05-14 | 95.78M shares derived: average of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | 96.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 95.85M shares derived: average of 2 quarters · filed 2025-03-20 | 95.54M shares derived: average of 3 quarters · filed 2025-03-20 | 95.22M shares 10-K · filed 2025-03-20 | ||
| 2023-09-30 | 95.58M shares 10-Q · filed 2024-11-13 | 95.24M shares derived: average of 2 quarters · filed 2024-11-13 | 94.91M shares 10-Q · filed 2024-11-13 | 88.20M shares derived: average of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | 94.91M shares 10-Q · filed 2024-08-06 | 94.57M shares 10-Q · filed 2024-08-06 | 85.74M shares derived: average of 3 quarters · filed 2024-08-06 | 72.00M shares derived: average of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | 94.23M shares 10-Q · filed 2024-05-09 | 81.16M shares derived: average of 2 quarters · filed 2024-05-09 | 64.36M shares derived: average of 3 quarters · filed 2024-05-09 | 55.92M shares derived: average of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | 68.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 49.42M shares derived: average of 2 quarters · filed 2024-03-21 | 43.15M shares derived: average of 3 quarters · filed 2024-03-21 | 39.96M shares 10-K · filed 2024-03-21 | ||
| 2022-09-30 | 30.76M shares 10-Q · filed 2023-11-09 | 35.46M shares 10-Q · filed 2022-11-02 | 30.68M shares derived: average of 2 quarters · filed 2023-11-09 | 30.58M shares 10-Q · filed 2023-11-09 | 35.25M shares 10-Q · filed 2022-11-02 | 25.64M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 30.61M shares 10-Q · filed 2023-08-10 | 30.49M shares 10-Q · filed 2023-08-10 | 23.94M shares derived: average of 3 quarters · filed 2023-08-10 | 26.70M shares derived: average of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | 30.37M shares 10-Q · filed 2023-05-15 | 20.60M shares derived: average of 2 quarters · filed 2023-05-15 | 25.40M shares derived: average of 3 quarters · filed 2023-05-15 | |||
| 2021-12-31 | 10.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 22.92M shares derived: average of 2 quarters · filed 2023-03-23 | 28.87M shares 10-K · filed 2023-03-23 | |||
| 2021-09-30 | 35.00M shares 10-Q · filed 2022-11-02 | 34.88M shares 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |